Groote KD, Prenen H. Intrahepatic therapy for liver-dominant metastatic colorectal cancer. World J Gastrointest Oncol 2015; 7(9): 148-152 [PMID: 26380058 DOI: 10.4251/wjgo.v7.i9.148]
Corresponding Author of This Article
Hans Prenen, MD, Professor of Medicine, Department of Gastroenterology, University Hospitals Leuven, Herestraat 49, B-3000 Leuven, Belgium. hans.prenen@uzleuven.be
Research Domain of This Article
Oncology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Sep 15, 2015; 7(9): 148-152 Published online Sep 15, 2015. doi: 10.4251/wjgo.v7.i9.148
Intrahepatic therapy for liver-dominant metastatic colorectal cancer
Kerlijne De Groote, Hans Prenen
Kerlijne De Groote, Hans Prenen, Department of Gastroenterology, University Hospitals Leuven, B-3000 Leuven, Belgium
Author contributions: De Groote K and Prenen H contributed equally to this work.
Conflict-of-interest statement: No conflict of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Hans Prenen, MD, Professor of Medicine, Department of Gastroenterology, University Hospitals Leuven, Herestraat 49, B-3000 Leuven, Belgium. hans.prenen@uzleuven.be
Telephone: +32-16-340238 Fax: +32-16-344419
Received: March 21, 2015 Peer-review started: March 22, 2015 First decision: July 1, 2015 Revised: July 6, 2015 Accepted: July 29, 2015 Article in press: August 3, 2015 Published online: September 15, 2015
Abstract
In patients with metastatic colorectal cancer, the liver is the most common site of metastatic disease. In patients with liver-dominant disease, consideration needs to be given to locoregional treatments such as hepatic arterial infusion chemotherapy, transarterial chemoembolisation and selective internal radiation therapy because hepatic metastases are a major cause of liver failure especially in chemorefractory disease. In this review we provide insights on the published literature for locoregional treatment of liver metastases in metastatic colorectal cancer.
Core tip: Thanks to the increased chemotherapeutic options in patients with metastatic colorectal cancer (mCRC), the overall survival has significantly improved the last decade. Liver failure is a common cause of death in mCRC with liver metastases. Therefore in these patients locoregional treatment is a valuable treatment option in order to increase survival. In this review we provide insights on the published literature.
